Introducing IV-EQUIVALENT DIURESIS* IN THEIR COMFORT ZONE

IV-EQUIVALENT DIURESIS DELIVERED AT HOME1

THE SAFETY AND EFFICACY OF SUBCUTANEOUS FUROSCIX WAS ESTABLISHED BASED ON SIMILAR SYSTEMIC EXPOSURE WHEN COMPARED TO IV FUROSEMIDE.1

a person using the on-body infusor

ON-BODY INFUSOR EASE OF USE1,2

In a study of FUROSCIX usability, 98.3% of participants reported no difficulty understanding or following Instructions for Use.2

the FUROSCIX infusor

SINGLE-USE, PRE-PROGRAMMED, AND DISPOSABLE1

FUROSCIX Infusor will deliver only an 80-mg dose over 5 hours† via a pre-programmed, single-use Infusor with prefilled cartridge that should be properly disposed of when infusion is complete.

*based on similar systemic exposure and diuresis

†30 mg over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.

FUROSCIX has demonstrated efficacy similar to IV furosemide diuresis.

Learn More

References: 1. FUROSCIX [prescribing information]. Burlington, MA: scPharmaceuticals Inc.; 2022. 2. Andre AD, Mohr J, Cornelius B, et al. 2020. Successful validation of a wearable, on-body infusor for subcutaneous administration of Furoscix® in heart failure patients, caregivers, and health care practitioners. [Poster]. The HFSA Virtual Annual Scientific Meeting, September 30 – October 6, 2020.